Physician profile
Edward C Cameron
NPI 1447285499
$2,112.45
in general payments reported to CMS, 2019-2025
16 companies · $17.13 in 2025
The $17.13 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $301 · 2020: $125 · 2021: $244 · 2022: $586 · 2023: $557 · 2024: $283 · 2025: $17.13.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $857.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $857.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $614.05 | 2019-2025 | Rinvoq, Skyrizi, Linzess |
| Janssen Biotech, INC. | $414.28 | 2019-2024 | Stelara, Remicade, Simponi |
| Merck Sharp & Dohme LLC | $222.51 | 2019-2024 | Dificid |
| Takeda Pharmaceuticals U.S.A., INC. | $169.57 | 2019-2023 | Entyvio |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $166.29 | 2020-2024 | Trulance, Xifaxan |
| Celgene Corporation | $101.25 | 2022-2024 | Zeposia |
| Gilead Sciences, INC. | $92.44 | 2019-2021 | |
| Ironwood Pharmaceuticals, INC | $75.29 | 2019-2023 | Linzess |
| Redhill Biopharma INC. | $68.28 | 2020-2021 | |
| Qol Medical, LLC | $55.64 | 2024 | Sucraid |
| Intercept Pharmaceuticals, INC. | $55.64 | 2022-2024 | Ocaliva |
| Allergan, INC. | $19.76 | 2020 | |
| Fresenius Kabi USA, LLC | $16.68 | 2023 | Idacio |
| Regeneron Healthcare Solutions, INC. | $14.60 | 2022 | |
| Boston Scientific Corporation | $14.43 | 2022 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $11.74 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edward Cameron listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.